⚙️ Technology

SARS-CoV-2

1 story First seen Jul 19, 2026 Latest Jul 19, 2026

🧬 AI profile — grown from 6ic coverage SARS-CoV-2 is a novel coronavirus strain that caused the COVID-19 pandemic, primarily affecting human respiratory systems. Research on SARS-CoV-2 has led to various studies on treatments and management of post-COVID-19 conditions, including Long COVID. The recent breakthrough in Long COVID treatment involves a potential link between the antidepressant fluvoxamine and reduced fatigue in patients affected by SARS-CoV-2.

Coverage by desk

Science 1

Coverage · last 14 days

Jul 7Jul 20

Recurring themes

long COVID ×1 fluvoxamine ×1 McMaster University ×1 Brazil ×1 clinical trial ×1

🕸 Connection map 🌌 Full galaxy →

Connected entities

McMaster University ×1 Brazil ×1 COVID ×1 University of British Columbia ×1 REVIVE-TOGETHER ×1 Fluvoxamine ×1 Brazilian ×1 Stanford University ×1 Metformin ×1

Every story (1)

Breakthrough in Long COVID Treatment: Fluvoxamine Shows Promise in Reducing Fatigue

Science · Jul 19, 2026 · BlockchainSpace AI